Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 2
2001 3
2002 2
2003 2
2004 2
2005 1
2006 2
2007 3
2008 1
2009 3
2010 4
2011 1
2012 4
2013 4
2014 3
2015 4
2016 2
2017 4
2018 5
2019 7
2020 6
2021 5
2022 11
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Ganaxolone.
[No authors listed] [No authors listed] 2022 Nov 30. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Nov 30. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 35349236 Free Books & Documents. Review.
No published information is available on the clinical use of ganaxolone during breastfeeding. However, a study by the manufacturer indicates that amounts in breastmilk appear to be low and would not be expected to cause any adverse effects in breastfed infants....
No published information is available on the clinical use of ganaxolone during breastfeeding. However, a study by the manufacturer in …
Ganaxolone: First Approval.
Lamb YN. Lamb YN. Drugs. 2022 Jun;82(8):933-940. doi: 10.1007/s40265-022-01724-0. Drugs. 2022. PMID: 35596878 Review.
Oral ganaxolone is also currently undergoing phase III evaluation in the treatment of tuberous sclerosis complex-related epilepsy, while an intravenous formulation of ganaxolone is being evaluated in refractory status epilepticus. This article summarizes the milesto …
Oral ganaxolone is also currently undergoing phase III evaluation in the treatment of tuberous sclerosis complex-related epilepsy, wh …
Ganaxolone: A New Treatment for Neonatal Seizures.
Yawno T, Miller SL, Bennet L, Wong F, Hirst JJ, Fahey M, Walker DW. Yawno T, et al. Front Cell Neurosci. 2017 Aug 22;11:246. doi: 10.3389/fncel.2017.00246. eCollection 2017. Front Cell Neurosci. 2017. PMID: 28878622 Free PMC article. Review.
In this mini-review, we present evidence in support of the use of ganaxolone, a GABA(A) agonist neurosteroid, as a novel neonatal therapy. ...We suggest that ganaxolone is an ideal anti-seizure treatment because it can be safely used prospectively, with minimal or n …
In this mini-review, we present evidence in support of the use of ganaxolone, a GABA(A) agonist neurosteroid, as a novel neonatal the …
PCDH19-Related Epilepsy Syndrome: A Comprehensive Clinical Review.
Samanta D. Samanta D. Pediatr Neurol. 2020 Apr;105:3-9. doi: 10.1016/j.pediatrneurol.2019.10.009. Epub 2019 Nov 30. Pediatr Neurol. 2020. PMID: 32057594 Review.
A phase 3 clinical study is currently active to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone (an allopregnanolone analog) therapy....
A phase 3 clinical study is currently active to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone (an allopreg …
[New antiepileptic drugs].
Vidaurre J, Herbst J. Vidaurre J, et al. Medicina (B Aires). 2019;79 Suppl 3:48-53. Medicina (B Aires). 2019. PMID: 31603844 Free article. Review. Spanish.
Cannabidiol and fenfluramine are useful in the treatment of Dravet or Lennox Gastaut syndrome. Allopregnenolona and ganaxolone showed good efficacy in status epilepticus and could play an important future role in this clinical scenario....
Cannabidiol and fenfluramine are useful in the treatment of Dravet or Lennox Gastaut syndrome. Allopregnenolona and ganaxolone showed …
The efficacy and safety of ganaxolone for the treatment of refractory epilepsy: A meta-analysis from randomized controlled trials.
Meng J, Yan Z, Tao X, Wang W, Wang F, Xue T, Liu Y, Wang Z. Meng J, et al. Epilepsia Open. 2023 Mar;8(1):90-99. doi: 10.1002/epi4.12669. Epub 2022 Nov 15. Epilepsia Open. 2023. PMID: 36333279 Free PMC article.
OBJECTIVE: Epilepsy is one of the most common and refractory neurological disorders globally. Ganaxolone, a neuroactive steroid that enhances GABAergic inhibition, has been tested in many trials for the resolution of refractory epilepsy. ...For safety outcomes, adverse eve …
OBJECTIVE: Epilepsy is one of the most common and refractory neurological disorders globally. Ganaxolone, a neuroactive steroid that …
Anti-apoptotic Actions of Allopregnanolone and Ganaxolone Mediated Through Membrane Progesterone Receptors (PAQRs) in Neuronal Cells.
Thomas P, Pang Y. Thomas P, et al. Front Endocrinol (Lausanne). 2020 Jun 24;11:417. doi: 10.3389/fendo.2020.00417. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32670200 Free PMC article. Review.
New data show that low concentrations (20 nM) of ganaxolone also activate mPRdelta signaling and exert anti-apoptotic actions through this receptor. Preliminary evidence suggests that ganaxolone can also exert neuroprotective effects by activating inhibitory G prote …
New data show that low concentrations (20 nM) of ganaxolone also activate mPRdelta signaling and exert anti-apoptotic actions through …
Novel antidepressant drugs: Beyond monoamine targets.
Gonda X, Dome P, Neill JC, Tarazi FI. Gonda X, et al. CNS Spectr. 2023 Feb;28(1):6-15. doi: 10.1017/S1092852921000791. Epub 2021 Sep 30. CNS Spectr. 2023. PMID: 34588093 Review.
Several other glutamatergic (AXS-05, REL-1017, AV-101, SLS-002, AGN24175, and PCN-101) and GABAergic (brexanolone, zuranolone, and ganaxolone) drugs are currently in different stages of clinical development for MDD, TRD and other indications. ...
Several other glutamatergic (AXS-05, REL-1017, AV-101, SLS-002, AGN24175, and PCN-101) and GABAergic (brexanolone, zuranolone, and ganaxo …
Current and future pharmacotherapy options for drug-resistant epilepsy.
Elkommos S, Mula M. Elkommos S, et al. Expert Opin Pharmacother. 2022 Dec;23(18):2023-2034. doi: 10.1080/14656566.2022.2128670. Epub 2022 Sep 27. Expert Opin Pharmacother. 2022. PMID: 36154780 Review.
EXPERT OPINION: Current pharmacotherapy options for drug-resistant epilepsy include perampanel, brivaracetam and the newly approved cenobamate for focal epilepsies; cannabidiol (Epidiolex) for Lennox-Gastaut Syndrome (LGS), Dravet and Tuberous Sclerosis Complex (TSC); fenfluramin …
EXPERT OPINION: Current pharmacotherapy options for drug-resistant epilepsy include perampanel, brivaracetam and the newly approved cenobama …
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies.
Strzelczyk A, Schubert-Bast S. Strzelczyk A, et al. CNS Drugs. 2021 Jan;35(1):61-83. doi: 10.1007/s40263-020-00784-8. Epub 2021 Jan 21. CNS Drugs. 2021. PMID: 33479851 Free PMC article. Review.
Other treatments in clinical development include fenfluramine in late phase III, perampanel, soticlestat-OV953/TAK-953, carisbamate and ganaxolone. Non-pharmacologic interventions include the ketogenic diet, vagus nerve stimulation and surgical interventions; these are als …
Other treatments in clinical development include fenfluramine in late phase III, perampanel, soticlestat-OV953/TAK-953, carisbamate and g …
50 results